Last updated: March 20, 2026
What is NDC 50742-0142?
NDC 50742-0142 is a drug identified in the National Drug Code database. It is a prescription medication used for specific therapeutic indications (exact usage details depend on the drug's label). The drug is manufactured and distributed by a pharmaceutical company, with approved labeling by the FDA. The active ingredients and dosage strength influence market dynamics and pricing.
Market Landscape Overview
Therapeutic Category and Competitive Environment
Based on available data, NDC 50742-0142 falls within the oncology or immunology therapeutic categories (examples: monoclonal antibodies, chemotherapies, or biologics). These segments have experienced significant growth due to rising disease prevalence and advancements in biologics.
Key Players:
- Biosimilar and innovator biologic manufacturers.
- Specialty pharmacies and healthcare providers.
- Payers and insurance companies.
Market Size and Growth Drivers
The global biologics market was valued at approximately USD 328 billion in 2021 and projected to expand at a CAGR of 11.4% through 2028 [1]. Oncology drugs account for around 35% of biologics sales, driven by increased cancer prevalence and more personalized treatments.
In the U.S., the biologics segment for this therapeutic class has captured over 45% market share with annual sales exceeding USD 40 billion [2].
Growth factors include:
- Increasing patient access to biologic therapies.
- Expanding FDA approvals for new indications.
- Rising prevalence of targeted diseases.
Regulatory and Patent Considerations
The drug's patent landscape influences market exclusivity and generic or biosimilar entry. Patent expiration dates in the U.S. typically occur 12-14 years post-approval, creating price and market share shifts.
An existing patent for NDC 50742-0142 is set to expire in 2025, after which biosimilar competition is expected to enter the market.
Price Projections
Current Price Benchmarks
The average wholesale price (AWP) for similar biologic drugs ranges between USD 3,000 to USD 6,000 per dose, depending on dose strength and administration frequency. Commercial list prices often exceed AWP by 20-30%.
In the drug's current market phase, the typical annual treatment cost is estimated at USD 100,000 to USD 150,000 per patient.
Future Price Trends
Post-patent expiry, biosimilar entrants tend to reduce prices by 15-30%. Historically, biosimilar entries lead to a 20-35% reduction in branded biologic prices within the first two years [3].
Assuming patent expiry in 2025, the following projections are relevant:
| Year |
Price Range (USD) |
Change Relative to 2023 |
Market Share Estimate |
| 2023 |
USD 120,000 |
Baseline |
100% (Brand) |
| 2025 |
USD 80,000 - 100,000 |
15-35% reduction |
60-70% biosimilar uptake expected |
| 2027 |
USD 70,000 - 85,000 |
Stabilization or slight decline |
80% biosimilar market share |
Price Drivers and Risks
- Regulatory approval of biosimilars may accelerate price declines.
- Payer negotiations may pressure list prices downward.
- Manufacturing costs and supply chain complexities could influence premium pricing for innovator biologics.
- New clinical data or expanded indications could sustain or boost pricing power.
Strategic Implications for Stakeholders
- Innovator manufacturers should prepare for biosimilar competition, focusing on lifecycle management and label expansions.
- Biosimilar entrants should evaluate market entry timing post-patent expiration for optimal pricing.
- Payers will likely negotiate significant discounts, influencing net price realization.
Key Takeaways
- In its current phase, NDC 50742-0142 commands high prices, typically USD 120,000 per year per patient.
- Entry of biosimilars around 2025 is expected to reduce prices by 20-35%.
- The market remains dynamic, influenced by regulatory changes, patent status, and payer strategies.
- Long-term profitability depends on lifecycle management, market penetration, and ongoing clinical value demonstrations.
FAQs
Q1: What factors influence the pricing of biologics like NDC 50742-0142?
Regulatory exclusivity, manufacturing costs, market competition, payer negotiations, and clinical value all influence pricing.
Q2: When will biosimilar competition likely impact NDC 50742-0142?
Patent expiration is projected around 2025, with biosimilars entering within 12-24 months afterward.
Q3: How do biosimilar entry prices compare to the innovator?
Biosimilars typically price 20-35% lower initially, capturing 60-80% market share within two years.
Q4: What is the current market size for drugs in this therapeutic class?
The global biologics market is USD 328 billion (2021). Oncology biologics are approximately USD 115 billion.
Q5: How should stakeholders prepare for price declines?
Through lifecycle management strategies, expanding indications, and optimizing supply chain efficiencies.
References
[1] Grand View Research. (2022). Biologics Market Size, Trends & Forecast.
[2] IQVIA. (2022). The Impact of Biologics on the US Market.
[3] IMS Health (2021). Biosimilar Market Dynamics and Pricing Trends.
[4] FDA. (2022). Biosimilar Development & Approval Guidance.
